GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.80 (-0.98%)

Growth Price

Undervalued by 103.47%

Stability Price

Overvalued by 36.27%

Company Metrics

  • P/E 7.07
  • P/S 3.32
  • P/B 6.97
  • EPS 11.39
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.31%
  • Avg. Vol. 10.68M
  • Shares 1.52B
  • Market Cap. 106.32B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Analyst Perspectives: Gilead Sciences, Inc. (NASDAQ:GILD)
Post Registrar - 13 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) plunged -0.18% during previous trade, a total of 7,508,400 shares exchanged hands compared with its average trading volume of 10.68M shares whereas its relative volume is 0.71.
Gilead Sciences Inc. (GILD) Stock Rating Reaffirmed by Jefferies Group - The Cerbat Gem
Gilead Sciences Inc.'s Biggest Win in 2016 So Far - Motley Fool
How Risky Is Gilead Sciences Inc.?
Motley Fool - Sep 18, 2016
It has been a tough year to be a Gilead Sciences (NASDAQ:GILD) shareholder. Fears of incoming competition for the company's hepatitis C virus (HCV) treatments have been exacerbated by declining sales among its HCV drug-based treatments.
Gilead Sciences Inc Stock Has Huge Upside Potential - Amigobulls
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis - Business Wire (press release)
How Safe Is Gilead Sciences Inc. and Its Dividend?
Motley Fool - Sep 20, 2016
If you're looking for a stock that looks ridiculously cheap and has a dividend to boot, then Gilead Sciences (NASDAQ:GILD) is definitely a contender.
Gilead Sciences: A 'Slight Uplift' for R&D Strategy?
Barron's (blog) - 12 hours ago
These data, while not overwhelming, continue to support the potential of filgotinib as a treatment for Crohn's, and are likely to provide a slight uplift for Gilead's R&D strategy, which had recently taken a hit with the disclosure that the company was ...
Biotech Stocks Luring Investors Focus: Gilead Sciences Inc. (NASDAQ:GILD ... - Street Wise Report (press release) (blog)
Fitzroy Data Boosts R&D At GILD – Leerink - TCC
3 Reasons Gilead Sciences Inc. Stock Could Rise
Motley Fool - Sep 4, 2016
Put Epclusa at the top of the list of solid new market entrants for Gilead Sciences. It's the first all-oral drug that can treat all genotypes of hepatitis C. Epclusa is also the first approved treatment for hep C genotypes 2 and 3 that doesn't require ...
Gilead Sciences, Inc. (NASDAQ:GILD) Needs A New Rescue Plan - TCC
Gilead Sciences: If You Snooze, You Lose - Seeking Alpha
Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys
Motley Fool - Sep 7, 2016
If you're a growth-oriented investor, Gilead Sciences (NASDAQ:GILD) may no longer be a particularly good fit for your portfolio.
Berenberg Kicks Off Gilead Sciences, Inc. (GILD) Coverage at Buy - TCC
Gilead Sciences Inc. (GILD) Now Covered by Berenberg Bank - The Cerbat Gem
Gilead: Ways To Unlock Shareholder Value
Seeking Alpha - 15 hours ago
As Gilead (NASDAQ:GILD) itself says, it's not easy to develop a strong pipeline, especially when one already has created two amazing product lines.
Gilead Sciences Inc. Stock Will Rise Before Revenue Growth Returns
Amigobulls - Sep 15, 2016
Gilead Sciences, Inc. CEO John Milligan is bullish on the company's HIV products and pipeline. Sales in Q2 rose 15% to $3.1 billion.
Billionaire Battleground: Is It Time to Buy or Sell Gilead Sciences? - Motley Fool
Revenue Estimates Analysis: Gilead Sciences, Inc. (NASDAQ:GILD) - News Oracle
Gilead Sciences, Inc. (GILD) Remains Top Pick: Piper Jaffray
Smarter Analyst - Sep 22, 2016
Yesterday, Gilead Sciences, Inc. (NASDAQ:GILD) announced it was halting its Phase 2/3 clinical study of GS-5745, an anti-MMP9 antibody designed to treat patients with moderate to severe active ulcerative colitis.
The Process Of Valuation: Gilead Sciences
Seeking Alpha - Sep 22, 2016
This is where IOI comes in. I've spent more than 20 years looking at companies for hedge funds, investment banks and as an independent analyst with Morningstar and YCharts.